Abstract
Background: Non-Small Cell Lung Carcinoma is one of the major cause of morbidity and mortality worldwide with an incidence rate of 1.3 million cases per year. Heat shock protein 90 (HSP90) is a promising drug target in cancer treatment. HSP90 is required to activate numerous eukaryotic proto-oncogenic protein kinases, hence play a prominent role in cancer.
Method: We reviewed fifty-five articles to highlight the importance of HSP90 in NSCLC and the recent developments of its inhibitors.
Results: This review showed that HSP90 inhibitors i.e. Ganestespib have shown great potential in the treatment of non-small cell lung carcinoma (NSCLC). Different HSP90 inhibitors has been designed till date that acts as effective drugs in tumour suppression. However, the utility of these drugs has been limited due to several drawbacks including hepato-toxicity, poor solubility, and poorly tolerated formulations.
Conclusion: The goal of this review is to present the data in support of use of HSP90 inhibitors in NSCLC and to provide an overview of the on-going clinical trials involving new-generation HSP90 inhibitors.
Keywords: Heat shock protein 90, non-small-cell lung carcinoma, inhibitors, drugs, clinical trials, co-chaperons, mutations.
Graphical Abstract
Current Drug Metabolism
Title:Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
Volume: 19 Issue: 4
Author(s): Anam Akram, Sara Khalil, Sobia Ahsan Halim*, Hooria Younas, Sadaf Iqbal and Saima Mehar
Affiliation:
- Department of Biochemistry, Kinnaird College for Women, Lahore-54000,Pakistan
Keywords: Heat shock protein 90, non-small-cell lung carcinoma, inhibitors, drugs, clinical trials, co-chaperons, mutations.
Abstract: Background: Non-Small Cell Lung Carcinoma is one of the major cause of morbidity and mortality worldwide with an incidence rate of 1.3 million cases per year. Heat shock protein 90 (HSP90) is a promising drug target in cancer treatment. HSP90 is required to activate numerous eukaryotic proto-oncogenic protein kinases, hence play a prominent role in cancer.
Method: We reviewed fifty-five articles to highlight the importance of HSP90 in NSCLC and the recent developments of its inhibitors.
Results: This review showed that HSP90 inhibitors i.e. Ganestespib have shown great potential in the treatment of non-small cell lung carcinoma (NSCLC). Different HSP90 inhibitors has been designed till date that acts as effective drugs in tumour suppression. However, the utility of these drugs has been limited due to several drawbacks including hepato-toxicity, poor solubility, and poorly tolerated formulations.
Conclusion: The goal of this review is to present the data in support of use of HSP90 inhibitors in NSCLC and to provide an overview of the on-going clinical trials involving new-generation HSP90 inhibitors.
Export Options
About this article
Cite this article as:
Akram Anam , Khalil Sara, Halim Ahsan Sobia *, Younas Hooria , Iqbal Sadaf and Mehar Saima , Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC), Current Drug Metabolism 2018; 19 (4) . https://dx.doi.org/10.2174/1389200219666180307122441
DOI https://dx.doi.org/10.2174/1389200219666180307122441 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Application of Gene Therapy in Diabetes Care
Infectious Disorders - Drug Targets Investigations of Malignant Mesothelioma
Current Respiratory Medicine Reviews Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies
Anti-Cancer Agents in Medicinal Chemistry Isatoic Anhydride: A Fascinating and Basic Molecule for the Synthesis of Substituted Quinazolinones and Benzo di/triazepines
Current Organic Chemistry Design, Synthesis, and In vitro Antitumor Evaluation of Novel Phenylaminopyrimidine Derivatives
Medicinal Chemistry Signaling by Reactive Oxygen and Nitrogen Species in Skin Diseases
Current Drug Metabolism Combination of Photodynamic Therapy with Anti-Cancer Agents
Current Medicinal Chemistry AIDS in African Nonhuman Primate Hosts of SIVs: A New Paradigm of SIV Infection
Current HIV Research Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Enzymatic regulation and functional relevance of NOX5
Current Pharmaceutical Design MRI of Focal Liver Lesions
Current Medical Imaging The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) The Use of Bio-Active Compounds of Citrus Fruits as Chemopreventive Agents and Inhibitor of Cancer Cells Viability
Anti-Cancer Agents in Medicinal Chemistry Store-Operated Ca2+ Entry in Muscle Physiology
Current Chemical Biology